Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled study of nabiximols in MS spasticity
2020-004306-58Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Nabiximols (Sativex) with Placebo (2 arms). Primary endpoint: Change in spasm frequency. Started Nov 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2020-004306-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004306-58.